A new study demonstrates a novel role for an endocannabinoid in promoting hepatocyte steatosis. The study describes a mode of bidirectional communication between the alcohol-injured hepatocyte and the glutamate-activated hepatic stellate cell. This intercellular communication represents a novel targetable pathogenic mechanism that could lead to new strategies to prevent fatty liver disease progression to cirrhosis.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The endocannabinoid system promotes hepatocyte progenitor cell proliferation and maturation by modulating cellular energetics
Cell Death Discovery Open Access 25 March 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Asrani, S. K. et al. Burden of liver diseases in the world. J. Hepatol. 70, 151–171 (2019).
McPherson, S. et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J. Hepatol. 62, 1148–1155 (2015).
Parker, R. et al. Natural history of histologically proven alcohol-related liver disease: a systematic review. J. Hepatol. 71, 586–593 (2019).
Louvet, A. & Mathurin, P. Alcoholic liver disease: mechanisms of injury and targeted treatment. Nat. Rev. Gastroenterol. Hepatol. 12, 231–242 (2015).
Dam-Larsen, S. et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut. 53, 750–755 (2004).
Choi, W. M. et al. Glutamate signaling in hepatic stellate cells drives alcoholic steatosis. Cell Metab. https://doi.org/10.1016/j.cmet.2019.08.001 (2019).
Spooren, W. et al. Insight into the function of group I and group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disorders. Behav. Pharmacol. 14, 257–277 (2003).
Caraceni, P. et al. The endocannabinoid system and liver diseases. J. Neuroendocrinol. 20, 47–52 (2008).
Nguyen, T. et al. Overcoming the psychiatric side effects of the cannabinoid CB1 receptor antagonists: current approaches for therapeutics development. Curr. Top. Med. Chem. 19, 1418–1435 (2019).
Godlewski, G. et al. Targeting peripheral CB1 receptors reduces ethanol intake via a gut-brain axis. Cell Metab. 29, 1320–1333 (2019).
Acknowledgements
R.B. is supported by NIH/NIAAA grants AA026972, AA026978 and AA026264, and by NIH/NIDDK grant P30DK120531.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Argemi, J., Bataller, R. Hepatocyte–stellate cell synapse in alcohol-induced steatosis: another role for endocannabinoids. Nat Rev Gastroenterol Hepatol 17, 5–6 (2020). https://doi.org/10.1038/s41575-019-0233-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-019-0233-8